David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
The purpose of assessing dangerousness is to determine whether an individual poses a risk of endangering self or others now or in the near future and to identify what interventions are necessary to minimize that risk.
During the 1960s and '70s, the iconography of ads for antipsychotic drugs changed from former depictions of docile white women patients to depictions of hostile black men, reflecting transformations in how American culture viewed race and mental illness.
Eric Trupin, PhD, Sarah Cusworth Walker, PhD, Hathaway Burden, and Mary Helen Roberts
Mental health diversion programs show promise in effectively addressing the treatment needs of youth with mental health and substance use disorders who come in contact with the justice system.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.
Registries of those considered dangerous focus wrongly on those with mental illness, who account for only 4 percent of violent acts committed in the United States.
Is it ethical to create and advertise, either publicly or during office visits, package deals that offer patients an incentive to have procedures they are not already seeking and might not have considered?
Within the patient-physician relationship, the request for neuroenhancement becomes a chief concern, and the physician has a duty to take a history and perform a physical exam to determine whether the patient’s current level of function represents significant change.